Abstract
Background: High-grade gliomas are the most common and invasive malignant brain tumors in adults, and they are almost universally fatal because of drug resistance and recurrence. In spite of the progress in adjuvant therapy (like temozolomide) and irradiation after surgery, no effective salvage therapy is currently available for relapsed patients. A Korean herbal recipe MSC500 has been reported to have beneficial therapeutic effects in patients with high-grade gliomas who are relapsed or refractory to conventional treatments. But the underlying molecular mechanisms remain unclear. Methods: As Cancer stem cell (CSC) plays a pivotal role in the resistance to conventional cancer therapy, we explored the effects of MSC500 on the CSC-like side population (SP) in GBM8401 human glioblastoma multiforme cells. Results: Compared with the parental cells, the SP cells were more resistant to temozolomide but sensitive to MSC500. The mRNA levels of stemness genes such as Nanog, CD133, and ABCG2 were much higher in the SP cells, and so was E-cadherin, which was reported to correlate with the aggressiveness of glioblastoma multiforme. Treatment with MSC500 decreased the proportion of SP cells and high ALDH activity cells from 1.6% to 0.3% and from 0.9% to 0.1%, respectively, accompanied with suppression of the aforementioned stemness genes and E-cadherin, as well as other CSC markers such as ABCB5, Oct-4, Sox-2, β-catenin, Gli-1, and Notch-1. Conclusion: Our results suggest the potential role of MSC500 as an integrative and complementary therapeutic for advanced or refractory high-grade glioma patients.
| Original language | English |
|---|---|
| Pages (from-to) | 541-554 |
| Number of pages | 14 |
| Journal | Integrative Cancer Therapies |
| Volume | 13 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Nov 19 2014 |
Fingerprint
Keywords
- ALDH
- cancer stem cell
- E-cadherin
- glioma
- MSC500
ASJC Scopus subject areas
- Complementary and alternative medicine
- Oncology
- Medicine(all)
Cite this
Elimination of cancer stem-like side population in human glioblastoma cells accompanied with stemness gene suppression by Korean herbal recipe MSC500. / Yao, Chih Jung; Han, Tae Young; Shih, Ping Hsiao; Yi, Tsu Yi; Lai, I. Chun; Chang, Ken Hu; Lai, Tung-Iuan; Chang, Chia Lun; Lai, Gi Ming.
In: Integrative Cancer Therapies, Vol. 13, No. 6, 19.11.2014, p. 541-554.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Elimination of cancer stem-like side population in human glioblastoma cells accompanied with stemness gene suppression by Korean herbal recipe MSC500
AU - Yao, Chih Jung
AU - Han, Tae Young
AU - Shih, Ping Hsiao
AU - Yi, Tsu Yi
AU - Lai, I. Chun
AU - Chang, Ken Hu
AU - Lai, Tung-Iuan
AU - Chang, Chia Lun
AU - Lai, Gi Ming
PY - 2014/11/19
Y1 - 2014/11/19
N2 - Background: High-grade gliomas are the most common and invasive malignant brain tumors in adults, and they are almost universally fatal because of drug resistance and recurrence. In spite of the progress in adjuvant therapy (like temozolomide) and irradiation after surgery, no effective salvage therapy is currently available for relapsed patients. A Korean herbal recipe MSC500 has been reported to have beneficial therapeutic effects in patients with high-grade gliomas who are relapsed or refractory to conventional treatments. But the underlying molecular mechanisms remain unclear. Methods: As Cancer stem cell (CSC) plays a pivotal role in the resistance to conventional cancer therapy, we explored the effects of MSC500 on the CSC-like side population (SP) in GBM8401 human glioblastoma multiforme cells. Results: Compared with the parental cells, the SP cells were more resistant to temozolomide but sensitive to MSC500. The mRNA levels of stemness genes such as Nanog, CD133, and ABCG2 were much higher in the SP cells, and so was E-cadherin, which was reported to correlate with the aggressiveness of glioblastoma multiforme. Treatment with MSC500 decreased the proportion of SP cells and high ALDH activity cells from 1.6% to 0.3% and from 0.9% to 0.1%, respectively, accompanied with suppression of the aforementioned stemness genes and E-cadherin, as well as other CSC markers such as ABCB5, Oct-4, Sox-2, β-catenin, Gli-1, and Notch-1. Conclusion: Our results suggest the potential role of MSC500 as an integrative and complementary therapeutic for advanced or refractory high-grade glioma patients.
AB - Background: High-grade gliomas are the most common and invasive malignant brain tumors in adults, and they are almost universally fatal because of drug resistance and recurrence. In spite of the progress in adjuvant therapy (like temozolomide) and irradiation after surgery, no effective salvage therapy is currently available for relapsed patients. A Korean herbal recipe MSC500 has been reported to have beneficial therapeutic effects in patients with high-grade gliomas who are relapsed or refractory to conventional treatments. But the underlying molecular mechanisms remain unclear. Methods: As Cancer stem cell (CSC) plays a pivotal role in the resistance to conventional cancer therapy, we explored the effects of MSC500 on the CSC-like side population (SP) in GBM8401 human glioblastoma multiforme cells. Results: Compared with the parental cells, the SP cells were more resistant to temozolomide but sensitive to MSC500. The mRNA levels of stemness genes such as Nanog, CD133, and ABCG2 were much higher in the SP cells, and so was E-cadherin, which was reported to correlate with the aggressiveness of glioblastoma multiforme. Treatment with MSC500 decreased the proportion of SP cells and high ALDH activity cells from 1.6% to 0.3% and from 0.9% to 0.1%, respectively, accompanied with suppression of the aforementioned stemness genes and E-cadherin, as well as other CSC markers such as ABCB5, Oct-4, Sox-2, β-catenin, Gli-1, and Notch-1. Conclusion: Our results suggest the potential role of MSC500 as an integrative and complementary therapeutic for advanced or refractory high-grade glioma patients.
KW - ALDH
KW - cancer stem cell
KW - E-cadherin
KW - glioma
KW - MSC500
UR - http://www.scopus.com/inward/record.url?scp=84921054632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921054632&partnerID=8YFLogxK
U2 - 10.1177/1534735414549623
DO - 10.1177/1534735414549623
M3 - Article
C2 - 25359730
AN - SCOPUS:84921054632
VL - 13
SP - 541
EP - 554
JO - Integrative Cancer Therapies
JF - Integrative Cancer Therapies
SN - 1534-7354
IS - 6
ER -